ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

ClinicalTrials.gov ID: NCT00930930

Public ClinicalTrials.gov record NCT00930930. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 12:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.

Study identification

NCT ID
NCT00930930
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Enrollment
145 participants

Conditions and interventions

Conditions

Interventions

  • Venous blood draw Procedure
  • cisplatin Drug
  • everolimus Drug
  • paclitaxel Drug
  • placebo Other

Procedure · Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2009
Primary completion
Sep 30, 2013
Completion
Sep 30, 2014
Last update posted
May 6, 2015

2009 – 2014

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
University of Alabama Birmingham Alabama 35249
University of Mississippi Medical Center Research Institute Jackson Mississippi 39213
Hershey Medical Center Hershey Pennsylvania 17033
Vanderbilt-Ingram Cancer Center - Cool Springs Nashville Tennessee 37064
MBCCOP - Meharry Medical College - Nashville Nashville Tennessee 37208
Vanderbilt-Ingram Cancer Center Nashville Tennessee 37232-6838
The Methodist Hospital Research Institute Houston Texas 77030
University of Virginia Health Sciences Center Charlottesville Virginia 22098

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00930930, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 6, 2015 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00930930 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →